Effect of Trendelenburg Positioning on Anesthesia-Induced Hypotension in Elderly Patients
Launched by ZHEJIANG CANCER HOSPITAL · May 3, 2025
Trial Information
Current as of June 26, 2025
Not yet recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how a specific position called the Trendelenburg position can help prevent low blood pressure, or hypotension, in elderly patients during surgery. The trial will involve patients aged 65 to 90 years who are scheduled for abdominal surgery with general anesthesia. Some patients will be placed in the Trendelenburg position, where their legs are elevated, while others will remain lying flat (the supine position) when the anesthesia starts. Researchers will closely monitor blood pressure during the first 15 minutes after anesthesia to see which position better keeps blood pressure stable.
To be eligible for this trial, patients must be between 65 and 90 years old, have a scheduled abdominal surgery, and be in generally good health (classified as ASA physical status I to III). However, some people may not qualify if they have certain health issues, such as difficulties with breathing or swallowing, or if they cannot provide consent for participation. It's important for potential participants and their families to understand that this trial is designed to improve care for older adults during surgery by finding better ways to manage blood pressure.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • patients aged 65-90 years
- • scheduled for abdominal surgery with general anesthesia
- • expected to have continuous radial arterial pressure monitoring
- • American Society of Anesthesiologists (ASA) physical status I to III
- Exclusion Criteria:
- • contraindications or failure of radial arterial catheterization
- • expected possible difficult airway
- • non-sinus rhythm
- • increased intracranial pressure
- • patients at high risk of regurgitation or aspiration
- • inability to provide consent
About Zhejiang Cancer Hospital
Zhejiang Cancer Hospital is a leading medical institution in China, dedicated to advancing cancer research, treatment, and patient care. As a prominent clinical trial sponsor, the hospital focuses on innovative therapies and evidence-based practices to improve outcomes for cancer patients. With a multidisciplinary team of experienced oncologists and researchers, Zhejiang Cancer Hospital is committed to fostering collaboration and leveraging cutting-edge technology in its clinical trials. The institution aims to contribute significantly to the global understanding of cancer and enhance therapeutic options through rigorous research and development initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Hangzhou, Zhejiang, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported